Why We Need Medical Professionals in Investing

Medical professionals who pursue careers in investing can help support the biotech companies that create treatments that improve, and save, lives.

A six-month-old baby grabs his toes while lying on his back.
(Image credit: Getty Images)

Blake and Julia’s son was born in May 2012. He seemed to be a healthy baby, but within a few months his parents noticed that he wasn’t rolling. A series of doctors’ appointments led to genetic testing, which revealed that their son had spinal muscular atrophy (SMA), a degenerative — and fatal — neuromuscular condition. There were no effective treatments for SMA; most babies with the diagnosis didn’t make it to the age of 1. Their little boy died in January 2013.

At the time, I was an equity research analyst at an investment firm, watching SMA closely. My firm was looking for ways to invest in innovative treatments for the condition.

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

This article was written by and presents the views of our contributing adviser, not the Kiplinger editorial staff. You can check adviser records with the SEC or with FINRA.

To continue reading this article
please register for free

This is different from signing in to your print subscription

Why am I seeing this? Find out more here

Kyle Rasbach, PhD, PharmD
Managing Director of Eventide Ventures and Senior Research Analyst at Eventide Investments

Kyle Rasbach, PhD, PharmD, serves as a Managing Director for Eventide Ventures and a Senior Research Analyst for other Eventide investments. Dr. Rasbach has extensive experience in clinical pharmacology, basic science and health care equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery and medical devices.